Compare Archer-Daniels-Midland Co (ADM) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Archer-Daniels-Midland Co vs ResMed Inc. — how do they compare? Archer-Daniels-Midland Co trades at $79.75 (market cap $38.78B), while ResMed Inc. trades at $225.59 (market cap $32.61B). The key difference: Archer-Daniels-Midland Co is the larger of the two by market cap, and Archer-Daniels-Midland Co pays the higher dividend (2.59%). Which is the better fit depends on your goals.
| ADM | RMD | |
|---|---|---|
Market Cap | $38.78B | $32.61B |
Sector | Consumer Staples | Health |
52-Week High | $87.32 | $293.73 |
52-Week Low | $56.00 | $182.82 |
Enterprise Value | $47.03B | $31.97B |
Dividend Yield | 2.59% | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADM trades at $79.72, down 0.96% on the day, with a bullish technical signal and strong recent earnings beats. The stock shows solid fundamentals with a P/E of 21.98 and P/S of 0.48, while revenue for 2025 was $80.27B. Recent news highlights growth in biofuels and crushing margins, with the company raising its 2026 earnings outlook after a strong Q2.
The outlook is positive, supported by raised guidance and operational strength, but risks include execution challenges and margin pressures. Analysts maintain a consensus price target of $88.00, indicating potential upside from current levels amid a predominantly hold rating sentiment.
ResMed (RMD) trades at $225.17, up 2.33% today, reflecting strong recent earnings beats and robust fundamentals. The stock exhibits a bullish technical trend, supported by positive moving averages, with key resistance near $227. Financially, the company shows impressive growth, with Q4 2026 revenue reaching a record $1.5 billion (Reuters, 2026-08-07) and a net income margin of 26.94%. Recent strategic moves include the divestiture of the MatrixCare business to sharpen focus on core sleep and respiratory care markets.
The outlook for RMD is positive, driven by consistent earnings outperformance and strategic portfolio optimization. However, investors face risks from weaker-than-expected fiscal 2027 revenue guidance and competitive pressures in the medtech sector. The consensus price target of $235.00 (MarketBeat, 2026-08-09) suggests modest upside potential, supported by a majority analyst hold rating amid solid long-term growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Archer-Daniels-Midland Co
Archer-Daniels Midland is a major processor of oilseeds, corn, wheat, and other agricultural commodities. Additionally, the company owns an extensive network of logistical assets to store and transport crops around the globe. ADM also runs a nutrition business that focuses on both human and animal ingredients. The company is also a large producer of corn-based sweeteners, starches, and ethanol.
Read more on ADM →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
